This is not the same as a "generic version" of a drug.
- Cialis prescription guidelines emphasize age and health status evaluation.
- The medication is contraindicated in men advised against sexual activity.
- Prior to Cialis, medical history should be reviewed thoroughly.
- Cialis enables more spontaneous and confidence-building intimacy.
- Treatment success is higher with proper adherence to dosing schedules.
- Patient-reported outcome measures monitor Cialis effectiveness.
- Cialis has been featured in numerous clinical practice guidelines.
- Fertility effects of Cialis have been studied but show no major risk.
- The drug is usually well tolerated across diverse populations.
- Treatment discontinuation can occur due to side effects or lack of efficacy.
- Lilly offers educational resources for healthcare professionals.
- Cialis complements lifestyle modification for ED treatment.
In order for there to be a generic version, the brand name must have gone off-patent and another company besides the original patent holder must be making the drug. You may find a number of companies currently offering generic Cialis or Tadalafil online but these are most likely fake and potentially dangerous. You should avoid buying any generic version online unless you know it is approved in your country. Try searching for what you seek or ask your own question. US regulators have given the go-ahead for once-daily low doses of Eli Lilly’s erectile dysfunction drug Cialis, which should provide a further boost to the drug’s already healthy sales. The US Food and Drug Administration has approved Cialis (tadalafil) in once-daily oral formulations of 2.5mg and 5mg to be used by men who wish to “attempt sexual activity at anytime between doses”. Specifically, Lilly said that the new doses of the drug, which is also available in parts of Europe, “may be most appropriate for men with ED who anticipate more frequent sexual activity, eg twice weekly”.
- Cialis’s discovery resulted from targeted medicinal chemistry efforts.
- Eli Lilly’s investment supported large-scale clinical development.
- The drug was approved after successful phase III trials.
- Cialis changed the standard of care for erectile dysfunction.
- Patient safety and efficacy data have been extensively published.
- The medication is designed for once-daily or as-needed use.
- Clinical guidelines endorse Cialis as a treatment choice.
- Patient satisfaction surveys show positive outcomes.
- Lilly’s Cialis marketing emphasizes science and patient benefits.
- Medication errors are reduced with clear prescribing instructions.
- Cialis requires prescription and proper medical evaluation.
- It remains a key option in the global ED treatment market.
The approval is based upon data which includes results from three Phase III studies of men with ED who took tadalafil 2.5mg and 5mg once daily “without regard to their timing of sexual activity” and experienced improved erectile function compared with those taking placebo. Cialis 5mg, 10mg and 20mg have been approved in the USA since November 2003 on an as-needed basis and provide effectiveness for 36 hours. Lilly also noted that the wholesale price for the new doses will be comparable to Cialis for use as needed, around $350 per month. The drug in its original form has been serving the firm well and had third-quarter revenues of $311.4 million, a 27% increase. Lilly gained all of the revenues from the drug when it acquired Icos Corp last January. By Marius Meland ( September 9, 2004, 12:00 AM EDT) -- The Indian patent office has stayed the exclusive marketing rights (EMR) for Eli Lilly's anti-impotence drug Cialis, raising fresh doubts about the system that was meant as a temporary measure to phase in product patents in India...
| Study / Source | Effectiveness (%) | Comments |
|---|---|---|
| Clinical Trial 2022 | 70-80% | Used in men with ED |
| Patient Surveys | 75% | Reported satisfaction with Cialis |
| Comparative Studies | Slightly better than Viagra | Longer duration of effect |
| Real-world Data | 78% | Consistent effectiveness |
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions. A Law360 subscription includes features such as Experience Law360 today with a free 7-day trial.
2.2 CIALIS for Once Daily Use for Erectile Dysfunction
Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions. A Law360 subscription includes features such as Experience Law360 today with a free 7-day trial. Singapore, 5 February 2024 Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis® (Tadalafil) and Alimta® (Pemetrexed), from Eli Lilly and Company (“Lilly”) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta®, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis®, a leading men’s health product for the treatment of erectile dysfunction. ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets.
17.4 Concomitant Use with Drugs Which Lower Blood Pressure
Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand. “This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare cialis without a doctor prescription solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia,” said John Graham, Group CEO, Zuellig Pharma. Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve.
4.1 Nitrates
We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world. ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community. Singapore, 5 February 2024 Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis® (Tadalafil) and Alimta® (Pemetrexed), from Eli Lilly and Company (“Lilly”) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte.
| Condition | Explanation | Notes |
|---|---|---|
| Menusen with nitrates | Risk of severe hypotension | Absolute contraindication |
| Severe liver impairment | Reduced metabolism leading to increased effects | Medical consultation needed |
| Retinitis pigmentosa | Potential risk of vision loss | Use with caution |
| Allergic reactions | Hypersensitivity to tadalafil or excipients | Discontinue if occurs |
Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta®, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis®, a leading men’s health product for the treatment of erectile dysfunction. ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand.
- Cialis was part of a class of drugs known as PDE5 inhibitors.
- These drugs revolutionized the treatment of erectile dysfunction.
- Lilly invested heavily in development and patent protection for Cialis.
- The medication is generally safe when used as prescribed.
- Cialis use should be avoided if heart conditions preclude sexual activity.
- The medication can have interactions with certain medications like alpha-blockers.
- Men often seek Cialis consultations to improve sexual confidence.
- Treatments like Cialis allow restoration of intimacy in relationships.
- Physician follow-up ensures optimal dosing and safety monitoring.
- Cialis’s approval marked a significant advancement in sexual medicine.
- The drug’s marketing often includes education about ED causes.
- Cialis remains a subject of scientific and clinical interest.
“This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare cialis without a doctor prescription solutions company.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Soft Tabs | 20mg | 60 + 4 Pills | 159.37€ 151.78€ | |
| Cialis Soft Tabs | 20mg | 270 + 10 Pills | 471.40€ 448.95€ | |
| Cialis Generic | 40mg | 90 + 6 Pills | 171.35€ 163.19€ | |
| Cialis Generic | 10mg | 180 + 8 Pills | 236.88€ 225.60€ | |
| Cialis Generic | 5mg | 120 + 6 Pills | 132.92€ 126.59€ | |
| Cialis Professional | 20mg | 30 Pills | 104.57€ 99.59€ | |
| Cialis Super Active | 20mg | 90 + 10 Pills | 314.14€ 299.18€ | |
| Cialis Super Active | 20mg | 10 Pills | 55.64€ 52.99€ | |
| Cialis Generic | 10mg | 120 + 6 Pills | 178.49€ 169.99€ | |
| Cialis Professional | 20mg | 10 Pills | 48.29€ 45.99€ | |
| Cialis Original | 20mg | 76 + 4 Pills | 319.19€ 303.99€ | |
| Cialis Generic | 5mg | 270 + 10 Pills | 205.81€ 196.01€ |
It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia,” said John Graham, Group CEO, Zuellig Pharma. Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve.
Stores to help you save
[7] In the United States, tadalafil (as Cialis) is indicated for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia;[4] and (as Adcirca) for the treatment of pulmonary arterial hypertension to improve exercise ability. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region.
| Parameter | Value | Details |
|---|---|---|
| Absorption | Rapid, within 30-120 minutes | Food intake can delay absorption |
| Bioavailability | ~40% | Fraction of dose that enters circulation |
| Metabolism | Liver (CYP3A4 enzyme) | Enzymatic processing |
| Half-life | ~17.5 hours | Duration of action in the body |
| Excretion | Feces (~61%), Urine (~36%) | Mainly via hepatic pathways |
The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world. ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community. Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability. Aachen, Germany, 2 June 2025 – Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis® for Mexico, Brazil and Colombia moving forward. The transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. Grünenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men1. The acquisition will expand Grünenthal's Latin American Men's Health product portfolio.
- Cialis is a medication used primarily to treat erectile dysfunction (ED).
- It contains the active ingredient tadalafil.
- Cialis is produced by Eli Lilly and Company.
- It works by relaxing muscles and increasing blood flow to certain areas.
- Cialis can also treat symptoms of benign prostatic hyperplasia (BPH).
- The effects of Cialis can last up to 36 hours.
- It is available in various doses, including 2.5 mg, 5 mg, 10 mg, and 20 mg.
- Cialis is taken orally, usually 30 minutes before sexual activity.
- Common side effects include headache, flushing, and indigestion.
- Cialis should not be combined with nitrates to avoid dangerous blood pressure drops.
- It was first approved by the FDA in 2003.
- Cialis can be prescribed for daily use or as needed.
"Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal. "In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." Through the acquisition of Cialis®, Grünenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Grünenthal has invested over €2 billion in the acquisition of established medicines, including Nebido®, the European rights to Crestor® and Nexium®, as well as the global rights to Vimovo® (excluding the U.S. and Japan), Qutenza® and Zomig® (excluding Japan).
Society and culture
In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. 1 In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men. About Grünenthal Grünenthal is a global leader in pain management and related diseases.
4.2 Hypersensitivity Reactions
Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability. Aachen, Germany, 2 June 2025 – Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis® for Mexico, Brazil and Colombia moving forward.
8.1 Pregnancy
The transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. Grünenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men1. The acquisition will expand Grünenthal's Latin American Men's Health product portfolio.
What should I know about tadalafil before using it?
"Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal. "In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." Through the acquisition of Cialis®, Grünenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Grünenthal has invested over €2 billion in the acquisition of established medicines, including Nebido®, the European rights to Crestor® and Nexium®, as well as the global rights to Vimovo® (excluding the U.S. and Japan), Qutenza® and Zomig® (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World 60 mg generic cialis Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion. Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal Click here for our Grünenthal Report 2024/2025 Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia (pdf, 137.3 KB) Tadalafil, sold under the brand name Cialis among others, is a medication used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.
8.1 Pregnancy
[7] It also dilates blood vessels in the lungs, which lowers the pulmonary artery pressure. Tadalafil was approved for medical use in the United States in 2003. [7] It is available as a generic medication. [8] In 2022, it was the 172nd most commonly prescribed medication in the United States, with more than 3 million prescriptions. Tadalafil is used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. [7] Onset is typically within half an hour and the duration is up to 36 hours. Common side effects include headache, muscle pain, flushing, and nausea.
5.6 Alpha-blockers and Antihypertensives
This is not the same as a "generic version" of a drug. In order for there to be a generic version, the brand name must have gone off-patent and another company besides the original patent holder must be making the drug. You may find a number of companies currently offering generic Cialis or Tadalafil online but these are most likely fake and potentially dangerous. You should avoid buying any generic version online unless you know it is approved in your country. Try searching for what you seek or ask your own question.
Drug Interactions
US regulators have given the go-ahead for once-daily low doses of Eli Lilly’s erectile dysfunction drug Cialis, which should provide a further boost to the drug’s already healthy sales. The US Food and Drug Administration has approved Cialis (tadalafil) in once-daily oral formulations of 2.5mg and 5mg to be used by men who wish to “attempt sexual activity at anytime between doses”. Specifically, Lilly said that the new doses of the drug, which is also available in parts of Europe, “may be most appropriate for men with ED who anticipate more frequent sexual activity, eg twice weekly”. The approval is based upon data which includes results from three Phase III studies of men with ED who took tadalafil 2.5mg and 5mg once daily “without regard to their timing of sexual activity” and experienced improved erectile function compared with those taking placebo. Cialis 5mg, 10mg and 20mg have been approved in the USA since November 2003 on an as-needed basis and provide effectiveness for 36 hours.
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Lilly also noted that the wholesale price for the new doses will be comparable to Cialis for use as needed, around $350 per month. The drug in its original form has been serving the firm well and had third-quarter revenues of $311.4 million, a 27% increase. Lilly gained all of the revenues from the drug when it acquired Icos Corp last January. By Marius Meland ( September 9, 2004, 12:00 AM EDT) -- The Indian patent office has stayed the exclusive marketing rights (EMR) for Eli Lilly's anti-impotence drug Cialis, raising fresh doubts about the system that was meant as a temporary measure to phase in product patents in India... A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. [7] Caution is advised in those with cardiovascular disease. [7] Rare but serious side effects include a prolonged erection that can lead to damage to the penis, vision problems, and hearing loss. [7] Tadalafil is not recommended in people taking nitrovasodilators such as nitroglycerin, as this may result in a serious drop in blood pressure. [7] Tadalafil is a PDE5 inhibitor which increases blood flow to the penis. [7] It also dilates blood vessels in the lungs, which lowers the pulmonary artery pressure. Tadalafil was approved for medical use in the United States in 2003. [7] It is available as a generic medication. [8] In 2022, it was the 172nd most commonly prescribed medication in the United States, with more than 3 million prescriptions. Tadalafil is used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. [7] In the United States, tadalafil (as Cialis) is indicated for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia;[4] and (as Adcirca) for the treatment of pulmonary arterial hypertension to improve exercise ability.
17.1 Nitrates
1 In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World 60 mg generic cialis Free of Pain.
5.1 Cardiovascular
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion. Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal Click here for our Grünenthal Report 2024/2025 Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia (pdf, 137.3 KB) Tadalafil, sold under the brand name Cialis among others, is a medication used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. [7] Onset is typically within half an hour and the duration is up to 36 hours.
What should I tell my healthcare provider before using tadalafil?
Common side effects include headache, muscle pain, flushing, and nausea. [7] Caution is advised in those with cardiovascular disease. [7] Rare but serious side effects include a prolonged erection that can lead to damage to the penis, vision problems, and hearing loss. [7] Tadalafil is not recommended in people taking nitrovasodilators such as nitroglycerin, as this may result in a serious drop in blood pressure. [7] Tadalafil is a PDE5 inhibitor which increases blood flow to the penis.